Lattice_grid_med
Powered by LatticeGrid

Search Enter term and hit return. Use '*' for as a wildcard.

Publication Listing for the MeSH term infusion. Found 19 abstracts

Wong SJ, Winter K, Meropol NJ, Anne PR, Kachnic L, Rashid A, Watson JC, Mitchell E, Pollock J, Lee RJ, Haddock M, Erickson BA, Willett CG. RADIATION THERAPY ONCOLOGY GROUP 0247: A RANDOMIZED PHASE II STUDY OF NEOADJUVANT CAPECITABINE AND IRINOTECAN OR CAPECITABINE AND OXALIPLATIN WITH CONCURRENT RADIOTHERAPY FOR PATIENTS WITH LOCALLY ADVANCED RECTAL CANCER. International Journal of Radiation Oncology Biology Physics. 2012 Mar;82(4):1367-75.   PMCID: PMC3208721
Hassan R, Cohen SJ, Phillips M, Pastan I, Sharon E, Kelly RJ, Schweizer C, Weil S, Laheru D. Phase I Clinical Trial of the Chimeric Anti-Mesothelin Monoclonal Antibody MORAb-009 in Patients with Mesothelin-Expressing Cancers. Clinical Cancer Research. 2010 Dec;16(24):6132-8.   PMCID: PMC3057907
McGuire WP, Blessing JA, Bookman MA, Lentz SS, Dunton CJ. Topotecan has substantial antitumor activity as first-line salvage therapy in platinum-sensitive epithelial ovarian carcinoma: A Gynecologic Oncology Group study. Journal of Clinical Oncology. 2000 Mar;18(5):1062-7.
Bookman MA, Malmstrom H, Bolis G, Gordon A, Lissoni A, Krebs JB, Fields SZ. Topotecan for the treatment of advanced epithelial ovarian cancer: An open-label phase II study in patients treated after prior chemotherapy that contained cisplatin or carboplatin and paclitaxel. Journal of Clinical Oncology. 1998 Oct;16(10):3345-52.
McGuire WP, Ozols RF. Chemotherapy of advanced ovarian cancer. Seminars in Oncology. 1998 Jun;25(3):340-8.
Meropol NJ, Sonnichsen DS, Birkhofer MJ, Ferreira I, Noel D. Bioavailability and phase II study of oral UFT plus leucovorin in patients with relapsed or refractory colorectal cancer. Cancer Chemotherapy and Pharmacology. 1998 Mar;43(3):221-6.
Stevenson JP, Scher RM, Kosierowski R, Fox SC, Simmonds M, Yao KS, Green F, Broom C, Fields SZ, Krebs JB, O'Dwyer PJ. Phase II trial of topotecan as a 21-day continuous infusion in patients with advanced or metastatic adenocarcinoma of the pancreas. European Journal of Cancer. 1998 Aug;34(9):1358-62.
Langer CJ. The emerging role of paclitaxel and carboplatin in non-small cell lung carcinoma. In: Updates in Advances in Lung Cancer. 1997. p. 73-90.
Langer CJ, Millenson M, Rosvold E, Litwin S, McAleer CA, Bonjo CA, Ozols R. Paclitaxel (1-hour) and carboplatin (area under the concentration-time curve 7.5) in advanced non-small cell lung cancer: A phase II study of the Fox Chase Cancer Center and its network. Seminars in Oncology. 1997 Aug;24(4):81-8.
Langer CJ, Movsas B, Hudes R, Schol J, Keenan E, Kilpatrick D, Yeung C, Curran W. Induction paclitaxel and carboplatin followed by concurrent chemoradiotherapy in patients with unresectable, locally advanced non-small cell lung carcinoma: Report of Fox Chase Cancer Center Study 94-001. Seminars in Oncology. 1997 Aug;24(4):89-95.
Hageboutros A, Hudes GR, Brennan J, Green F, Hoffman J, LaCreta FP, Colofiore J, Martin DS, Ozols RF, Odwyer PJ. Phase I trial of fluorouracil modulation by N-phosphonacetyl-L- aspartate and 6-methylmercaptopurine ribonucleoside. Cancer Chemotherapy and Pharmacology. 1996 Jan;37(3):229-34.
Langer CJ, Millenson M, Odwyer P, Kosierowski R, Alexander R, Litwin S, McAleer CA, Bonjo CA, Ozols R. Combination paclitaxel (1-hour) and carboplatin (AUC 7.5) in advanced non-Small cell lung cancer: A phase II study by the Fox Chase Cancer Center Network. Seminars in Oncology. 1996 Dec;23(6):35-41.
Ozols RF. Paclitaxel (Taxol(R)) plus carboplatin as first-line treatment for advanced ovarian cancer. International Journal of Gynecological Cancer. 1996 Jan;6:9-12.
SutantoWard E, Arisawa Y, Tremiterra S, Sigurdson ER. Regional chemotherapy for colorectal hepatic metastases: Evidence for improved survival with new drug combinations. Annals of Surgical Oncology. 1996 Jan;3(1):36-43.
Byers K, Axelrod P, Michael S, Rosen S. Infections Complicating Tunneled Intraspinal Catheter Systems Used to Treat Chronic Pain. Clinical Infectious Diseases. 1995 Aug;21(2):403-8.
Scher RM, Kosierowski R, Lusch C, Alexander R, Fox S, Redei I, Green F, Raskay B, Amfoh K, Engstrom PF, Odwyer PJ. Phase II trial of topotecan in advanced or metastatic adenocarcinoma of the pancreas. Investigational New Drugs. 1995 Jan;13(4):347-54.
Arisawa Y, Sutantoward E, Dalton RR, Sigurdson ER. Short-Term Intrahepatic Fudr Infusion Combined with Bolus Mitomycin-C - Reduced Risk for Developing Drug-Resistance. Journal of surgical oncology. 1994 Jun;56(2):75-80.
Haas NB, Hines JB, Hudes GR, Johnston N, Ozols RF, O'Dwyer PJ. Phase I trial of 5-fluorouracil by 24-hour infusion weekly. Investigational New Drugs. 1993 Jan;11(2-3):181-5.
Odwyer PJ, Langer CJ, Walczak J, Levy MH, Padavicshaller K, Hudes GR, Litwin S, Comis RL. Phase-Ii Study of Weekly 5-Fluorouracil, Cisplatin and Vinblastine in Advanced Non-Small-Cell Lung-Cancer. European Journal of Cancer. 1991 Dec;27(12):1589-93.
The above publications are sorted by year, faculty last name, and first author. Click on any highlighted author listed to find all publications attributed to that individual. Click on the publication title to see the abstract. First authors who are faculty are highlighted like this. Last authors who are faculty are highlighted like this. Other authors who are faculty are highlighted like this.

MeSH cloud from publications including the MeSH term infusion

infusion chemotherapy randomized trial carcinoma 5-fluorouracil cisplatin colorectal cancer cancer oncology-group fluorouracil survival colorectal-cancer trial topotecan cyclophosphamide paclitaxel therapy drug liver metastases plasma pancreatic cancer 3-hour phase-ii inhibitor cells toxicity ii carboplatin hepatic metastases methylmercaptopurine riboside 1- colon cancer animal model phase 1 clinical trial solid tumors peritoneal mesothelioma ss1p taxol plus carboplatin lung-cancer experience ovarian cancer ovarian-cancer Cancer infusional therapy adenocarcinoma recombinant platinum anti-tumor activity Rectal preoperative radiotherapy Chemotherapy 5-fluorouridine phase-i hepatic arterial camptothecin riboside uracil invitro hyperfractionated radiation-therapy intrathecal morphine dna topoisomerase-i vindesine combination chemotherapy cancer pain ftorafur sparfosic acid hepatic arterial chemotherapy UFT cpt-11 biochemical modulation cooperative-oncology-group Radiotherapy phosphonacetyl-L-aspartate hickman platinum-resistant disease adenocarcinomas xenografts fluorodeoxyuridine uptake immunotoxin arterial phase II study b- gynecologic-oncology-group mitomycin C chemoradiation hyperfractionated radiation- radiotherapy phase II trial rat long-term diagnosis combination treatment n-(phosphonacetyl)-l-aspartic acid Neoadjuvant regimen analogs chemosensitivity tumor inhibition metastasis pharmacokinetics tegafur pathological complete response long leucovorin management opioids (2-tetrahydrofuryl)-5-fluorouracil topoisomerase-i mtt assay floxuridine epidural FUdR opiates catheter regimens phase-iii i phase- colony-stimulating factor pancreatic-cancer combination hepatic intraarterial floxuridine chemoradiotherapy continuous diastereoisomers fluorodeoxyuridine marker folinic acid paclitaxel taxol
Last updated on Monday, July 13, 2020